Drug Profile
Research programme: recombinant Bifidobacterium anticancer therapeutics - Anaeropharma Science
Alternative Names: anti-4-1BB scFV - Anaeropharma Science; APS-001; B. longum producing anti-4-1BB scFV - Anaeropharma Science; BEST-CD; BifidobactErial Selective Targeting-Cytosine Deaminase therapy; FGF2 producing B. longum - Anaeropharma ScienceLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Anaeropharma Science
- Developer Anaeropharma Science; Eisai Co Ltd
- Class Anti-ischaemics; Antineoplastics; Immunotherapies
- Mechanism of Action CD137 antigen agonists; Cytotoxic T-lymphocyte antigen 4 inhibitors; Fibroblast growth factor replacements; Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Peripheral arterial disorders
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Peripheral-arterial-disorders in Japan (IV)
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in Japan (IV)
- 21 Apr 2018 Preclinical data in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR - 2018)